Pharma Focus Asia

Aitia and UCB Announce Strategic Drug Discovery Collaboration

Thursday, March 16, 2023

UCB and Aitia announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntingdon’s disease. The collaboration seeks to validate novel drug targets that are causally linked to clinical endpoints in Huntington's disease.

This strategic collaboration will combine the use of novel Huntington’s disease drug targets from Aitia’s Gemini Digital Twins with UCB’s expertise in drug research and preclinical model systems in neurodegeneration with the aim to accelerate the discovery of new therapies for people living with Huntington's disease.

This collaboration will be an investment in next generation science and technology, allowing to accelerate the understanding of human pathobiology and explore the potential of developing novel medicines through AI. Moreover this collaborate gains deeper insights into the underlying mechanisms of this complex disease and hope to drive major advancements in drug discovery and development faster than ever before.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024